Our laboratory utilizes DNA sequencing, gene expression profiling, proteomic analyses, flow cytometric methodology and many other basic techniques to pursue goals that are ultimately translatable for improving health and overall survival in patients with brain cancer. Although our research is primarily focused on malignant glioma, with a special emphasis on glioblastoma, we are also interested in pursuing incurable pediatric brain tumors, as well as metastatic tumors that invade the brain/spinal cord. It is our sincere hope that, the basic mechanistic investigations that we carry out, uncover important and meaningful discoveries that translate into highly effective immunotherapeutic modalities for the benefit of patients with incurable cancer in the brain. Read more about us
To watch video in larger size, click the YouTube logo on the video.
News & Events
Congratulations to Dr. Erik Ladomersky, PhD, for his new manuscript in Clinical Cancer Research that supports the soon-to-open Phase I/IIa clinical trial in glioblastoma patients at Northwestern Medicine!
Please join us for the 2018 Northwestern Brain Tumor Institute Symposium.
Dr. Wainwright participated in an expert session on immunotherapy for glioblastoma
Congratulations, Lijie, on your manuscript accepted by Cellular and Molecular Immunology entitled, ‘IDO1 in cancer: a Gemini of immune checkpoints’
Congratulations to Dr. Alicia Lenzen, MD, for receiving the Second Year Fellow Translational Research Award at the 13th Annual Children's Hospital Research Day!!
Dr. Wainwright joins international leaders in immunotherapy for cancer in an Expert Round Table Discussion.
Congratulations to Postdoctoral Fellow, Dr. Erik Ladomersky,
Please join Dr. Wainwright at the 5th Annual Immuno-Oncology Summit August 31st at
Congratulations to Dr. Erik Ladomersky,
Please join us for the 2017 Northwestern Brain Tumor Institute Symposium.
Please join us Thursday, February 16th, for the Inaugural Cancer Immunology Working Group Meeting led by Drs. Sosman and Wainwright.
Congratulations Dr. Lijie Zhai,
'Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma'.
Please join us on Wednesday, January 18th as Dr. Wainwright presents clinical trial data for immunotherapy of primary brain tumors in Developmental Therapeutics Program Grand Rounds.
Congratulations to the Wainwright Laboratory for being awarded a 2017 Dixon Translational Research Grant for research entitled 'Investigating the Immunotherapeutic Potential of Esophageal Cancer’.
Congratulations to Dr. Erik Ladomersky,
Congratulations Dr. Lijie Zhai for receiving the Katten Muchin Rosenman Travel Scholarship for your work on identifying IDO1 as a prognostic factor in GBM patients!
Congratulations to the Wainwright Laboratory for being awarded a Clinic and Laboratory Integration Program grant from a preeminent Cancer Immunotherapy research organization: The Cancer Research Institute (CRI)! The research is entitled ‘IDO1 in glioblastoma: Translating work from mouse to man’, and has been awarded ‘in recognition of the outstanding quality and promise of your (Wainwright Lab’s) research’.
Congratulations to Erik Ladomersky,
Congratulations to Alicia Lenzen, MD, for being awarded a TL1 Multidisciplinary Training Program in Child and Adolescent Health from the Northwestern University Clinical and Translational Sciences (NUCATS) Institute. The award is for her research in developing a nanotherapeutic approach targeting immunosuppressive IDO1 for treatment of children with
Congratulations to the Wainwright Laboratory for being awarded their first R01 research grant entitled, “IDO1 and Immunotolerance in Glioblastoma”, from the NIH/National Institute of Neurological Disorders and Stroke
In collaboration with Drs. Chad Mirkin, Bin Zhang and Alex Stegh, the Wainwright Laboratory has been awarded funds through the IDP/ Sherman Fairchild Research Award to develop
Profile of Matthew Genet and his Student Research Fellowship award
Congratulations Lijie Zhai on being awarded 2nd Place in the 2016 Yao Yuan Biotech-Pharma Symposium for his Poster Presentation entitled, ‘Interactions between IDO1 and immune checkpoint blockade in a model of glioblastoma’
Congratulations Matthew Genet on being awarded a 2016 Carolyn L. Kuckein Student Research Fellowship from the Alpha Omega Alpha Honor Medical Society! Matthew's research is titled 'The Role of IDO1 in Human Glioblastoma'.
Please attend the upcoming Microbiology-Immunology Departmental seminar on Thursday, February 11 (2:00-3:
Please join us at the upcoming 2016 Northwestern Brain Tumor Institute CME Symposium on April 1st, 2016, between 7:15am-3:
A recent gift from Curing Kids Cancer and the Lurie Children’s Hospital pediatric neuro-oncologists, Drs. Fangusaro and
The work of Derek Wainwright,
Dr. Wainwright discusses
Congratulations toRebecca Angoyarfor being awarded a Weinberg College Summer Research Grant!
Ladomersky E, Zhai L, Lenzen A,
Zhai L, Ladomersky E, Lenzen A, Nguyen B, Patel R, Lauing KL,
Zhai L, Ladomersky E,
Binder DC, Wainwright DA. 2017.The Boosting Potential of Bacteria in Cancer Immunotherapy.Trends in MolecularMedicine. Jul;23(7):580-582.
Young J, Chmura SJ, Wainwright DA, Yamini B, Peters KB, Lukas R. Management of glioblastoma in elderly patients. Journal of Neurological Sciences. In Press. Accepted on 7-30-17
Wainwright DA, Horbinski C, Hashizume R, James CD. 2017. Therapeutic hypothesis testing with rodent brain tumor models. Neurotherapeutics. Apr;14(2):385-392. PMID: 28321824
Zhai L, Ladomersky E, Dostal CR,
Lenzen A, Zhai L,
Ladomersky E, Zhai L,
Ladomersky E, Genet M, Zhai L,
Zhai L, Spranger S, Binder DC,
Binder DC, Davis AA, Wainwright DA. 2015. Immunotherapy for cancer in the central nervous system: current and future directions. 5(2):e1082027. OncoImmunology.
Zhai L, Dey M,
Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim C, Tobias AL, Cheng Y, Kim J, Zhang L, Qiao J, Han Y, Lesniak MS. 2014. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4